Oxford BioDynamics Announces Board Departure as Largest Shareholder Maintains Strategic Role

Oxford BioDynamics (LSE:OBD) has confirmed that Stephen Diggle has stepped down from his position as a non-executive director with immediate effect, concluding a nine-year tenure on the board. The move follows previously communicated intentions and aligns with standard corporate governance practices regarding long-serving directors.

Operational and financial highlights

Although Diggle has exited the board, his investment firm, Vulpes Investment Management, remains Oxford BioDynamics’ largest shareholder. The firm intends to appoint a replacement non-executive director in due course, ensuring it continues to exert meaningful influence over governance and strategic oversight. This continuity comes at a key stage for the company, as it advances the commercial rollout of its EpiSwitch-based diagnostic tests and works to strengthen its competitive position in the precision diagnostics market.

From an investment perspective, Oxford BioDynamics continues to face notable headwinds. The group is characterised by ongoing losses, elevated leverage and weak share price momentum. Valuation metrics offer little support, with a negative price-to-earnings ratio and no dividend yield, leaving financial performance as the dominant risk factor shaping the near- to medium-term outlook.

More about Oxford BioDynamics

Oxford BioDynamics Plc is an international biotechnology company specialising in precision clinical diagnostics. It develops and commercialises blood-based tests built on its proprietary EpiSwitch 3D genomics platform, which is designed to identify disease presence and predict patient response to treatment. Key products include the EpiSwitch PSE prostate cancer screening test, which enhances the accuracy of conventional PSA testing, and the EpiSwitch CiRT test, used to predict response to immuno-oncology checkpoint inhibitor therapies. The company is expanding its pipeline across oncology, neurology, inflammation, hepatology and animal health, and operates laboratories in Oxford (UK), Maryland (USA) and Penang (Malaysia), with its shares listed on AIM in London.